Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Chengdu Syncor Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market
Details : The agreement is expected to be a high-growth opportunity to supply Strontium89 in the Chinese market. Strontium89 is FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic...
Product Name : Metastron
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
July 03, 2022
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Chengdu Syncor Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Clionix
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.
Product Name : Metastron
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
December 07, 2021
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Clionix
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : isoSolutions
Deal Size : Undisclosed
Deal Type : Agreement
Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Product Name : Metastron
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : isoSolutions
Deal Size : Undisclosed
Deal Type : Agreement